Dr. Thomas Miller -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Thomas Miller, a Neurology physician based in City, CO. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Thomas Miller has received $142,279.01 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Thomas Miller has received a total of $142,279.01 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $142,279.01 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Thomas Miller's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Ownership Interest$142,279.01Ownership stakes, dividends, and investment returns

The largest payment category for Dr. Thomas Miller is Ownership Interest, accounting for 100% ($142,279.01) of total pharmaceutical payments received. This indicates a financial ownership interest in a pharmaceutical or medical device company.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Thomas Miller. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Eli Lilly and Company$142,279.011

Dr. Thomas Miller has a financial relationship with Eli Lilly and Company, receiving $142,279.01 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

Patient Guidance: Questions to Ask About Pharma Payments

If Dr. Thomas Miller is your physician and you have questions about their pharmaceutical industry payments, here are some constructive approaches:

Remember, pharmaceutical payments do not inherently indicate wrongdoing. Many payments support valuable activities like medical research, professional education, and clinical trial oversight. However, transparency empowers patients to have informed conversations with their healthcare providers.

Understanding Neurology Pharmaceutical Payments

Pharmaceutical payment patterns vary significantly by medical specialty. Neurology is a specialty where pharmaceutical companies frequently engage physicians for consulting, speaking, and research activities related to the treatments and devices used in this field.

When evaluating Dr. Thomas Miller's payment profile, it is important to compare against other Neurology physicians rather than doctors in unrelated fields. Specialists who work with expensive drugs, medical devices, or cutting-edge treatments typically receive higher payment volumes than primary care physicians, which reflects the nature of the specialty rather than any impropriety.

Geographic context also matters. Payment patterns in Colorado may differ from national averages due to local healthcare market dynamics, presence of academic medical centers, and the concentration of pharmaceutical company headquarters in the region.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Thomas Miller in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Eli Lilly and Company$142,279.01ownershipN/A2026-03-20Not Assessed

Frequently Asked Questions About Dr. Thomas Miller's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much has Dr. Thomas Miller received from pharmaceutical companies?

According to CMS Open Payments data, Dr. Thomas Miller has received a total of $142,279.01 in pharmaceutical industry payments across 1 recorded transactions. These payments came from 1 pharmaceutical companies.

What types of payments has Dr. Thomas Miller received?

Dr. Thomas Miller's payments include Ownership Interest ($142,279.01). Each payment type reflects a different kind of professional engagement with pharmaceutical companies.

Does receiving pharmaceutical payments mean Dr. Thomas Miller is compromised?

No. Receiving pharmaceutical payments does not inherently indicate wrongdoing or compromised medical judgment. Many payments support legitimate professional activities such as medical research, clinical trial oversight, continuing education, and advisory board participation. The Sunshine Act requires disclosure of these payments precisely so that patients can have transparent, informed discussions with their physicians about these financial relationships.

What is the NPI number 1031710622 for Dr. Thomas Miller?

NPI stands for National Provider Identifier. It is a unique 10-digit identification number issued by CMS (Centers for Medicare and Medicaid Services) to healthcare providers in the United States. Dr. Thomas Miller's NPI number 1031710622 uniquely identifies them across all CMS databases, including the Open Payments system that tracks pharmaceutical industry payments to physicians.

How can I verify Dr. Thomas Miller's pharmaceutical payment data?

All payment data shown on DoctorPharmaData comes from the official CMS Open Payments database, which is publicly available at openpaymentsdata.cms.gov. You can search for Dr. Thomas Miller using their NPI number (1031710622) to verify all payment records directly with the federal government's database. The data is updated annually with each new reporting cycle.

What is Neurology and how do pharma payments work in this field?

Neurology is a medical specialty practiced by Dr. Thomas Miller in City, CO. Pharmaceutical payments in neurology typically relate to the drugs, devices, and treatments used in this field. Companies may pay neurology specialists for consulting on drug development, speaking about treatments at medical conferences, conducting clinical research, or participating on scientific advisory boards.

Understanding This Doctor Payment Report

This transparency report for Dr. Thomas Miller is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Thomas Miller's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Thomas Miller and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.